Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 35462
![Lys-(Des-Arg9, Leu8)-Bradykinin (trifluoroacetate salt) ([Des-Arg10,Leu9]-Kallidin, [Des-Arg10,Leu9]-KD, Lys[Leu8]Des-Arg9-BK, Lys[Leu8]Des-Arg9-Bradykinin)](https://cdn2.caymanchem.com/cdn/productImages/35462.png)
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Lys-(Des-Arg9, Leu8)-Bradykinin is a bradykinin B1 receptor antagonist (Ki = 0.43 nM for the rabbit aorta receptor).1 It is selective for the bradykinin B1 over the B2 receptor (Ki = >10 µM for the rabbit ileum receptor).2 Lys-(Des-Arg9, Leu8)-Bradykinin inhibits contractions induced by the bradykinin B1 receptor agonist Des-Arg9-bradykinin (Item No. 31136) in isolated rabbit aortic rings (pA2 = 8.54).3 Intraperitoneal administration of Lys-(Des-Arg9, Leu8)-bradykinin (5 mg/kg per day for three days) reduces increases in paw edema in a rat model of arthritis induced by peptidoglycan-polysaccharide (PGPS).4
WARNING This product is not for human or veterinary use.
1. Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor. Biochim. Biophys. Acta 1264(2), 223-228 (1995).
2. Radioligand binding characterization of the bradykinin B2 receptor in the rabbit and pig ileal smooth muscle. Eur. J. Pharmacol. 635(1-3), 34-39 (2010).
3. Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J. Pharmacol. Exp. Ther. 266(1), 192-199 (1993).
4. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-